Literature DB >> 1294956

[Polycythemia after kidney transplantation].

D Hestin1, E Legrand, M Mertes, E Renoult, M Kessler.   

Abstract

Between 1971 and 1990, 251 kidney transplanted patients with a well functioning graft were evaluated to determine the frequency of post-transplant erythrocytosis (PTE). Thirty-one patients (13 percent) developed polycythaemia 10.6 +/- 10 months after transplantation. Thromboembolic complications occurred in 22 percent of the cases. The frequency of PTE was higher in males than in females (sex ratio: 7.2 vs 2.1; P < 0.05). Patients with renal dysplasia had a lower incidence of PTE (3 vs 22 percent; P < 0.05) as did those who had been treated with azathioprine (9.4 vs 19 percent; P < 0.05). None of the patients treated with recombinant erythropoietin before transplantation developed PTE during a mean follow-up of 15.1 +/- 4.5 months. The majority of polycythaemic patients had normal erythropoietin levels. These results show that there is an erythropoietin-independent proliferation due to an increased sensitivity of erythroid progenitors or to an erythroid stem cell stimulation by cytokines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1294956

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  2 in total

1.  Postrenal transplant erythrocytosis: further evidence implicating erythropoietin production by the native kidneys.

Authors:  R Martino; A Oliver; J M Ballarín; A F Remacha
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

2.  Contemporary incidence and risk factors of post transplant Erythrocytosis in deceased donor kidney transplantation.

Authors:  Sami Alasfar; Isaac E Hall; Sherry G Mansour; Yaqi Jia; Heather R Thiessen-Philbrook; Francis L Weng; Pooja Singh; Bernd Schröppel; Thangamani Muthukumar; Sumit Mohan; Rubab F Malik; Meera N Harhay; Mona D Doshi; Enver Akalin; Jonathan S Bromberg; Daniel C Brennan; Peter P Reese; Chirag R Parikh
Journal:  BMC Nephrol       Date:  2021-01-12       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.